Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.35% | 15.75% | 13.43% | 11.25% | -0.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.84% | 23.44% | 24.51% | 14.35% | -21.16% |
| Operating Income | -24.84% | -23.44% | -24.51% | -14.35% | 21.16% |
| Income Before Tax | -4.30% | -1.45% | 0.83% | -41.51% | -16.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.30% | -1.45% | 0.83% | -41.51% | -16.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.30% | -1.45% | 0.83% | -41.51% | -16.09% |
| EBIT | -24.84% | -23.44% | -24.51% | -14.35% | 21.16% |
| EBITDA | -25.17% | -23.76% | -24.73% | -14.40% | 20.95% |
| EPS Basic | 15.68% | 18.10% | 19.88% | -22.03% | -7.08% |
| Normalized Basic EPS | 13.03% | 15.29% | 7.78% | -37.73% | -12.99% |
| EPS Diluted | 14.93% | 17.75% | 21.26% | -16.27% | -2.03% |
| Normalized Diluted EPS | 13.03% | 15.29% | 7.78% | -37.73% | -12.99% |
| Average Basic Shares Outstanding | 21.82% | 23.05% | 23.87% | 17.65% | 9.84% |
| Average Diluted Shares Outstanding | 21.82% | 23.05% | 23.87% | 17.65% | 9.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
